Therapeutic Lymphangiogenesis Using Induced Cardiac Fibroblasts Protects the Heart From Heart Failure With Preserved Ejection Fraction Progression by Exerting Anti-Inflammatory and Antifibrotic Effects

20260 citationsJournal Articlediamond Open Access

Authors

Haihang Luo · Nagoya University

Yuuki Shimizu · Nagoya University

Takahiro Iwamiya · Symphogen (Denmark)

Yuimi Matsuoka · Symphogen (Denmark)

Xiyu Chen · Nagoya University

Tianyu Liu · Nagoya University

Yiyang Che · Nagoya University

Abstract

Cardiac lymphatic vessels play an important role in remodeling and function in HFpEF progression. Moreover, lymphangiogenesis could be a novel therapeutic target for HFpEF.

Topics & Keywords

Lymphatic System and Diseases Lymphatic Disorders and Treatments Vascular Malformations and Hemangiomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation Journal

DOI: 10.1253/circj.cj-25-0757

Field-Weighted Citation Impact: 0.00